Free Trial
NASDAQ:MIRA

MIRA Pharmaceuticals 11/12/2024 Earnings Report

MIRA Pharmaceuticals logo
$1.04 +0.05 (+4.61%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.04 +0.00 (+0.48%)
As of 04/25/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

MIRA Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MIRA Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

MIRA Pharmaceuticals' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

MIRA Pharmaceuticals Earnings Headlines

Mira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2
2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
See More MIRA Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

View MIRA Pharmaceuticals Profile

More Earnings Resources from MarketBeat